# A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Source: https://onco.cc/trials/nct05785741/  
OnCo record `nct05785741` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Trastuzumab, Osimertinib and Capecitabine in advanced solid tumours, run by DualityBio Inc., now recruiting.

## Summary

A Study of DB-1310 in Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05785741 by DualityBio Inc., with 1000 participants planned, started 2023-08-17 and due to reach its primary completion in 2027-12-30. Interventions recorded: DB-1310, Trastuzumab, Osimertinib and capecitabine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05785741
- Phase: 1/2
- Setting: A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 in Subjects With Advanced/Metastatic Solid Tumors
- Sponsor: DualityBio Inc.
- Enrolled: 1000

## Sources

- ClinicalTrials.gov NCT05785741: https://clinicaltrials.gov/study/NCT05785741

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- companies: [Duality Biotherapeutics](https://onco.cc/companies/dualitybio/)

---
JSON: https://onco.cc/api/v1/entities/nct05785741.json